The importance of hyperactivated MAPK for the generation of ER− breast tumours has been demonstrated by the fact that a MAPK signature is able to discriminate between ER+ and ER− breast tumours in four independent data sets with accuracies ranging from 68 to 87% (Creighton et al, 2006). The gene discussed is ESR1; the disease is breast neoplasm.